22148-82-9

Usage

Neuroprotective effects

MP4A has been investigated for its potential to protect neurons from damage and prevent neurodegeneration.

Role in preventing neurodegeneration

MP4A may help slow down or prevent the progression of neurodegenerative disorders, such as Parkinson's disease, by protecting neurons and maintaining neurotransmitter levels.

Ongoing research

The study of 1-Methyl-4-phenyl-butylamine is still in progress, with researchers working to better understand its potential benefits and applications in treating neurodegenerative disorders.

Value in understanding and treating neurodegenerative disorders

MP4A has the potential to be a valuable tool in the research and treatment of conditions like Parkinson's disease, as it targets a specific enzyme and has demonstrated neuroprotective properties.

Upstream product

• 377080-65-4 3-nitro-5-phenylpentan-2-ol 
• 377080-66-5 (E)-3-nitro-5-phenylpent-2-ene 
• 377080-79-0 (4R,1'R)-3-(1'-methyl-4'-phenylbutyl)-4-phenyloxazolidin-2-one 
• 42762-51-6 (E)-5-phenyl-3-penten-2-one 
• 22818-69-5 (3-nitropropyl)benzene 

Downstream Products

• 1237755-55-3 C₂₀H₂₅NO₃ 

Relevant academic research and scientific papers

Straightforward access to α-methylamines through cross-metathesis

A two-step procedure involving cross-metathesis and reductive amination enables easy access to -methylamines and α,α′-dimethyldiamines from a wide variety of terminal olefins. Georg Thieme Verlag Stuttgart · New York.

PURIN-6-ONE-DERIVATIVES

The compounds of a certain formula (I) in which e.g. R2, R3, R4 and R5 have the meanings as given below are novel effective PDE2 inhibitors. R2 is hydrogen, 1-4C-alkyl, 1-hydroxy-2-4C-alkyl, 1-4C-alkylcarbonyl or 1-(acetyloxy)-2-4C-alkyl and R3 is Arylbutyl, Heteroarylbutyl, Arylpropyl, Heteroarylpropyl, Arylethyl or Heteroarylethyl; wherein Aryl is phenyl, naphthalenyl or indanyl, each of which optionally substituted up to three times identically or differently by halogen, hydroxyl, nitro, trifluoromethyl, carboxyl, 1-4C-alkyl, 1-4C-alkoxy or 1-4C-alkoxycarbonyl, Heteroaryl is pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, quinazolinyl, quinoxalinyl, cinnolinyl, quinolyl, isoquinolyl, naphthyridinyl, phthalazinyl, indolyl, isoindolyl, indazolyl, purinyl, pteridinyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrrolyl, pyrazolyl, furanyl or thiophenyl, each of which optionally substituted up to three times identically or differently by halogen, hydroxyl, nitro, trifluoromethyl, carboxyl, 1-4C-alkyl, 1-4C-alkoxy or 1-4C-alkoxycarbonyl, R4 is 1-4C-alkoxy which is completely or predominantly substituted by fluorine and R5 is halogen, hydroxyl, nitro, trifluoromethyl, carboxyl, 1-4C-alkyl, 1-4C-alkoxy, 1 -4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino, mono- or di-1-4C-alkylamino, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, 1-4C-alkylcarbonyloxy, 1-4C-alkylsulfonylamino, phenylcarbonylamino, phenylcarbonylamino substituted in the phenyl moiety by R6 and/or R7, benzylcarbonylamino, benzylcarbonylamino substituted in the phenyl moiety by R8 and/or R9, phenylsulfonylamino, phenylsulfonylamino substituted in the phenyl moiety by R10 and/or R11, benzylsulfonylamino or benzylsulfonylamino substituted in the phenyl moiety by R12 and/or R13.

Enantioselective synthesis of α,α-disubstituted amines from nitroalkenes

Disubstituted nitroalkenes were converted into enantiomerically enriched amines (isolated as their hydrochloride salts) with enantiometric excesses of 88 to >95% in there steps: (a) highly stereoselective conjugate addition of the potassium salt of 4-phenyloxazolidin-2-one; (b) radical-mediated removal of the nitro group; (c) cleavage of the oxazolidinone.

Quaternary ammonium antiarrhythmic drugs

Quaternary ammonium salts of certain phenylbutylamines are useful antiarrhythmic drugs. A method for treating arrhythmia and prolonging the action potential of cardiac tissue is provided. Pharmaceutical formulations containing such quaternary ammonium salts are disclosed.